A review of thyroid hormone administration during adult donor care

Progress in Transplantation

Volumn 15, Issue 3, 2005, Pages 202-207

  Powner, David J ^a   Hernandez, Michael ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

THYROID HORMONE;

ADULT; BRAIN DEATH; CLINICAL PROTOCOL; DONOR; HORMONE SUBSTITUTION; HUMAN; LONG TERM CARE; METABOLISM; METHODOLOGY; PATIENT SELECTION; PHYSIOLOGY; REVIEW; STANDARD; TIME; TRANSPLANTATION; TREATMENT OUTCOME;

ADULT; BRAIN DEATH; CLINICAL PROTOCOLS; HORMONE REPLACEMENT THERAPY; HUMANS; LIFE SUPPORT CARE; PATIENT SELECTION; RESEARCH DESIGN; THYROID HORMONES; TIME FACTORS; TISSUE AND ORGAN PROCUREMENT; TISSUE DONORS; TREATMENT OUTCOME;

EID: 33644699298     PISSN: 15269248     EISSN: None     Source Type: Journal    
DOI: 10.7182/prtr.15.3.g52m58w20w8x2332     Document Type: Review

References (41)

1. Rosendale JD, Kauffman HM, McBride MA, et al. Hormonal resuscitation yields more transplanted hearts, with improved early function. Transplantation. 2003;75:1336-1341.
2. Montori VM, Guyatt GH. What is evidence-based medicine? Endocrinol Metab Clin North Am. 2002;31:521-526.
3. Guyatt GH, Haynes RB, Jaeschke RZ, et al. Users' guides to the medical literature: XXV. Evidence-based medicine: Principles for applying the users' guides to patient care. JAMA. 2000;284:1290-1296.
4. Khan KS, ter Riet G, Popay J, Nixon J, Kleijnen J. Stage II: Conducting the review phase 5: Study quality assessment. Available at: Http://www.york.ac. uk/inst/crd/report4.htm. Undertaking systematic reviews of research on effectiveness. Centre for Reviews and Dissemination. Cochrane Library, University of York, UK. Accessed March 9, 2004.
5. Novitzky D, Cooper DKC, Reichart B. Hemodynamic and metabolic responses to hormonal therapy in brain-dead potential organ donors. Transplantation. 1987;43:852-854.
6. Novitzky D, Cooper DKC, Chaffin JS, Greer AE, DeBault LE, Zuhdi N. Improved cardiac allograft function following triiodothyronine therapy to both donor and recipient. Transplantation. 1990;49:311-316.
7. Randell TT, Höckerstedt KAV. Triiodothyronine treatment is not indicated in brain-dead multiorgan donors: A controlled study. Transplant Proc. 1993;25:1552-1553.
8. Salim A, Vassiliu P, Velmahos GC, et al. The role of thyroid hormone administration in potential organ donors. Arch Surg. 2001;136:1377-1380.
9. Goarin JP, Cohen S, Riou B, et al. The effects of triiodothyronine on hemodynamic status and cardiac function in potential heart donors. Anesth Analg. 1996;83:41-47.
10. García-Fages LC, Cabrer C, Valero R, Manyalich M. Hemodynamic and metabolic effects of substitutive triiodothyronine therapy in organ donors. Transplant Proc. 1993; 25:3038-3039.
11. Orlowski JP, Spees EK. Improved cardiac transplant survival with thyroxine treatment of hemodynamically unstable donors: 95.2% graft survival at 6 and 30 months. Transplant Proc. 1993;25:1535.
12. Jeevanandam V, Todd B, Regillo T, Hellman S, Eldridge C, McClurken J. Reversal of donor myocardial dysfunction by triiodothryonine replacement therapy. J Heart Lung Transplant. 1994;13:681-687.
13. Jeevanandam V. Triiodothyronine: Spectrum of use in heart transplantation. Thyroid. 1997;7:139-145.
14. Rosendale JD, Kauffman HM, McBride MA, et al. Aggressive pharmacologic donor management results in more transplanted organs. Transplantation. 2003;75:482-487.
15. Kelly GS. Peripheral metabolism of thyroid hormones: A review. Altern Med Rev. 2000;5:306-333.
16. Farwell AP. Sick euthyroid syndrome. J Intensive Care Med. 1997;12:249-260.
17. Umpierrez GE. Euthyroid sick syndrome. South Med J. 2002;95:506-513.
18. Sugimoto T, Sakano T, Kinoshita Y, Masui M, Yoshioka T. Morphological and functional alterations of the hypothalamic- pituitary system in brain death with long term bodily living. Acta Neurochir. 1992;115:31-36.
19. Powner DJ, Hendrich A, Lagler RG, Ng RH, Madden RL. Hormonal changes in brain dead patients. Crit Care Med. 1990;18:702-708.
20. Koller J, Wieser C, Gottardis M, et al. Thyroid hormones and their impact on the hemodynamic and metabolic stability of organ donors and on kidney graft function after transplantation. Transplant Proc. 1990;22:355:357.
21. Karaylaçin K, Umana JP, Harrison JD, Buckels JAC, McMaster P, Mayer AD. Donor thyroid function does not affect outcome in orthotopic liver transplantation. Transplantation. 1994;57:669-672.
22. Macoviak JA, McDougall IR, Bayer MF, Brown M, Tazelaar H, Stinson EB. Significance of thyroid dysfunction in human cardiac allograft procurement. Transplantation. 1987;43:824-826.
23. Szostek M, Gaciong Z, Danielelewicz R, et al. Influence of thyroid function in brain stem death donors on kidney allograft function. Transplant Proc. 1997;29:3354-3356.
24. Mariot J, Sadoune LO, Jacob F, et al. Hormone levels, hemodynamics, and metabolism in brain dead organ donors. Transplant Proc. 1995;27:793-794.
25. Gifford RRM, Weaver AS, Burg JE, Romano PJ, Demers LM, Pennock JL. Thyroid hormone levels in heart and kidney cadaver donors. J Heart Transplant. 1986;5:249-253.
26. Powner DJ, Darby JM. Management of variations in blood pressure during care of organ donors. Prog Transplant. 2000; 10:25-32.
27. Powner DJ. Effects of gene induction and cytokine production in donor care. Prog Transplant. 2003;13:9-16.
28. Dujardin KS, McCully RB, Wijdicks EF, et al. Myocardial dysfunction associated with brain death: Clinical, echocardiographic, and pathologic features. J Heart Lung Transplant. 2001;20:350-357.
29. Birks EJ, Burton PBJ, Owen VJ, Latif N, Nyawo B, Yacoub MH. Molecular and cellular mechanisms of donor heart dysfunction. Transplant Proc. 2001;33:2749-2751.
30. Novitzky D. Selection and management of cardiac allograft donors. Curr Opin Cardiol. 1996;11:174-182.
31. Taniguchi S, Kitamura S, Kawachi K, Doi Y, Aoyama N. Effects of hormonal supplements on the maintenance of cardiac function in potential donor patients after cerebral death. Eur J Cardiothorac Surg. 1992;6:96-101.
32. Polikar R, Burger AG, Scherrer U, Nicod P. The thyroid and the heart. Circulation. 1993;87:1435-1441.
33. Ririe DG, Butterworth JF, Royster RL, MacGregor DA, Zaloga GP. Triiodothyronine increases contractility independent of ?- adrenergic receptors or stimulation of cyclic-3', 5'-Adenosine monophosphate. Anesthesiology. 1995;82:1004-1012.
34. Chen JM, Cullinane S, Spanier TB, et al. Vasopressin deficiency and pressor hypersensitivity in hemodynamically unstable organ donors. Circulation. 1999;100:244-246.
35. Pennefather SH, Bullock RE, Mantle D, Dark JH. Use of low dose arginine vasopressin to support brain-dead organ donors. Transplantation. 1995;59:58-62.
36. Dimopoulou I, Tsagarakis S, Anthi A, et al. High prevalence of decreased cortisol reserve in brain-dead potential organ donors. Crit Care Med. 2003;31:1113-1117.
37. Zaroff JG, Rosengard BR, Armstrong WF, et al. Maximizing use of organs recovered from the cadaver donor: Cardiac recommendations. Circulation. 2002;106:836-841.
38. Hunt SA, Baldwin J, Baumgartner W, et al. Cardiovascular management of a potential heart donor: A statement from the Transplantation Committee of the American College of Cardiology. Crit Care Med. 1996;24:1599-1601.
39. Powner DJ, Darby JM, Kellum JA. Proposed treatment guidelines for donor care. Prog Transplant. 2004;14:16-26.
40. Rosendale JD, Chabalewski FL, McBride MA, et al. Increased transplanted organs from the use of a standardized donor management protocol. Am J Transplant. 2002;2:761-768.
41. Wheeldon DR, Potter CDO, Oduro A, Wallwork J, Large SR. Transforming the "unacceptable" donor: Outcomes from the adoption of a standardized donor management technique. J Heart Lung Transplant. 1995;14:732-742.